Lakewood-amedex Biotherapeutics's ROI from its second quarter of 2026 to the second quarter of and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lakewood-amedex Biotherapeutics's ROI in the second quarter of 2026?
Lakewood-Amedex Biotherapeutics Inc. achieved a return on average invested assets (ROI) of 1764.78 % in its second quarter of 2026, this is above LABT's average return on investment of 0%.
Lakewood-amedex Biotherapeutics Inc. invested over the 12 months ending in its second quarter of 2026 $1 million

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.

Within the Healthcare sector Lakewood-Amedex Biotherapeutics Inc. achieved the highest return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. .

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Investment Change TTM	-	-	-	-	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	4	0	0	0	0
Return On Investment (TTM)	1764.78 %	-	8697.47 %	-	-
LABT's Overall Ranking	#	#	#	#	#
Seq. Investment Change TTM	-	-	-	-	-
Seq. Net Income Change TTM	27.64 %	544.78 %	111.79 %	-	-
Net Income (TTM) in Millions	18	14	2	1	0

LABT Company Profile >> Back to LABT Roi Comparisons >> See Annual LABT Return On Investment

Return On Investment LABT's Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Investment Statistics
High	Average	Low
0 %	0 %	0 %

Financial Statements
Lakewood-amedex Biotherapeutics's II. Quarter Investments	$ 4 Millions	LABT's Balance sheet
Lakewood-amedex Biotherapeutics's II. Quarter Income	$ 4 Millions	Quarterly LABT's Income Statement
LABT's Income by Division		See LABT's Income by Division

LABT Annual Return On Investment
Total Investments in Millions	-2	0	0	0	0
Y / Y Investment Growth	-	-	-	-	-
Net Income in Millions	0	0	0	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-	-	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LABT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LABT's Competitors
Subscribers only: Roi for Lakewood-amedex Biotherapeutics's Suppliers
Subscribers only: Return On Investment for LABT's Customers

Other Ratios
LABT's Roa	LABT's Inventory Turnover Ratio	LABT's Growth Rates	LABT's Dividend Statistics
	LABT's Profitability Ratios	LABT's Asset Turnover Ratio	LABT's Dividend Growth
LABT's Roe	LABT's Valuation Ratios	LABT's Financial Strength Ratios	LABT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Glucotrack Inc	843.28 %
Stablecoin Development Corporation	618.18 %

Date modified: 2026-09-12T06:29:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.